Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Literature DB >> 32908214

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Wen Shi Lee¹, Adam K Wheatley^1,2, Stephen J Kent^3,4,5, Brandon J DeKosky^6,7,8.

Abstract

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.

Entities: Chemical

Mesh：

Substances：

Year: 2020 PMID： 32908214 DOI： 10.1038/s41564-020-00789-5

Source DB: PubMed Journal: Nat Microbiol ISSN： 2058-5276 Impact factor: 17.745

84 in total

1. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple.

Authors: Fernando P Polack
Journal: Pediatr Res Date: 2007-07 Impact factor: 3.756

2. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors: H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal: Am J Epidemiol Date: 1969-04 Impact factor: 4.897

3. Vaccines against respiratory syncytial virus: The time has finally come.

Authors: Barney S Graham
Journal: Vaccine Date: 2016-05-13 Impact factor: 3.641

4. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins.

Authors: Tommy Tsan-Yuk Lam; Na Jia; Ya-Wei Zhang; Marcus Ho-Hin Shum; Jia-Fu Jiang; Yi-Gang Tong; Hua-Chen Zhu; Yong-Xia Shi; Xue-Bing Ni; Yun-Shi Liao; Wen-Juan Li; Bao-Gui Jiang; Wei Wei; Ting-Ting Yuan; Kui Zheng; Xiao-Ming Cui; Jie Li; Guang-Qian Pei; Xin Qiang; William Yiu-Man Cheung; Lian-Feng Li; Fang-Fang Sun; Si Qin; Ji-Cheng Huang; Gabriel M Leung; Edward C Holmes; Yan-Ling Hu; Yi Guan; Wu-Chun Cao
Journal: Nature Date: 2020-03-26 Impact factor: 49.962

5. Cross-reacting antibodies enhance dengue virus infection in humans.

Authors: Wanwisa Dejnirattisai; Amonrat Jumnainsong; Naruthai Onsirisakul; Patricia Fitton; Sirijitt Vasanawathana; Wannee Limpitikul; Chunya Puttikhunt; Carolyn Edwards; Thaneeya Duangchinda; Sunpetchuda Supasa; Kriangkrai Chawansuntati; Prida Malasit; Juthathip Mongkolsapaya; Gavin Screaton
Journal: Science Date: 2010-05-07 Impact factor: 47.728

6. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors: Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal: Lancet Date: 2020-01-30 Impact factor: 79.321

7. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors: Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal: Science Date: 2020-02-19 Impact factor: 47.728

8. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors: Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal: Science Date: 2020-03-04 Impact factor: 47.728

9. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

Authors: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Journal: Cell Discov Date: 2020-03-16 Impact factor: 10.849

10. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors: Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal: Cell Date: 2020-03-05 Impact factor: 41.582

216 in total

Review 1. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors: Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal: Front Microbiol Date: 2020-12-01 Impact factor: 5.640

2. SARS-CoV-2 B cell receptor signatures in at-risk populations.

Authors: Andrew I Flyak
Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808

3. Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2.

Authors: Donovan Guttieres; Anthony J Sinskey; Stacy L Springs
Journal: Antib Ther Date: 2021-03-20

4. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.

Authors: Belinda M Jackson-Thompson; Emilie Goguet; Eric D Laing; Cara H Olsen; Simon Pollett; K Monique Hollis-Perry; Santina E Maiolatesi; Luca Illinik; Kathleen F Ramsey; Anatalio E Reyes; Yolanda Alcorta; Mimi A Wong; Julian Davies; Orlando Ortega; Edward Parmelee; Alyssa R Lindrose; Matthew Moser; Elizabeth Graydon; Andrew G Letizia; Christopher A Duplessis; Anuradha Ganesan; Kathleen P Pratt; Allison M Malloy; David W Scott; Stephen K Anderson; Andrew L Snow; Clifton L Dalgard; John H Powers; David Tribble; Timothy H Burgess; Christopher C Broder; Edward Mitre
Journal: BMC Infect Dis Date: 2021-06-09 Impact factor: 3.090

5. The Immunopathobiology of SARS-CoV-2 Infection.

Authors: Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal: FEMS Microbiol Rev Date: 2021-11-23 Impact factor: 16.408

6. COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.

Authors: Jessica M Jones; Aiman J Faruqi; James K Sullivan; Cassandra Calabrese; Leonard H Calabrese
Journal: Pathog Immun Date: 2021-05-14

Review 10. Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors: Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal: Front Immunol Date: 2021-05-11 Impact factor: 7.561